Only Three Supplements Show Large Effects on Depression

For decades, people have reached for fish oil, vitamin pills, herbal extracts, or saffron in the hope of easing a dark mood without the side effects or stigma of prescription antidepressants. A sweeping new network meta-analysis throws cold and, at times, cautious light on that instinct: some compounds might help, but the evidence is thinner and messier than many headlines imply.

What the review actually did

Researchers pooled 163 randomized controlled trials that enrolled 15,757 adults diagnosed with major depressive disorder and tested 137 different nutrient-based or plant-derived treatments. These trials compared a wide range of nutraceuticals and phytoceuticals against placebo or standard antidepressants and measured symptom change, response rates, and treatment discontinuation.

The unusual twist: the authors did more than tally results. They examined study quality, hunted for outliers and publication bias, and recalculated effects after removing lower-quality evidence. That extra scrutiny revealed patterns that matter, because in depression research, study design shapes what you can trust.

Key findings and the candidates that stood out

After careful filtering, three treatments emerged as the most promising: eicosapentaenoic acid, or EPA; vitamin D3; and a specific St. John’s wort extract labeled ZE117. EPA had the deepest pool of data: twenty trials including 8,483 participants. Vitamin D3 and ZE117 showed benefit in smaller groups, three trials each, involving 344 and 207 people, respectively.

Other compounds flagged as potentially helpful in smaller or less consistent bodies of work included other St. John’s wort extracts, saffron, and curcumin. Saffron, for example, displayed larger effects in some studies, while curcumin was linked to modest reductions in anxiety symptoms co-occurring with depression. The authors noted biological plausibility for some of these results: saffron may increase brain-derived neurotrophic factor, or BDNF, and boost synaptic plasticity, processes that are often impaired in depression and anxiety.

How reliable are those results?

Not very, at least not yet. A clear pattern emerged: the larger the reported benefit, the more likely the underlying trial was to be lower quality. In other words, dramatic effects often came from studies with small sample sizes, inadequate blinding, or other methodological weaknesses. Once the authors removed higher-risk trials and statistical outliers, many apparent benefits shrank or disappeared.

The team described the remaining effect sizes for EPA, vitamin D3, and ZE117 as higher-than-expected for well-designed, double-blind trials. That phrasing implies skepticism. These compounds are candidates for further study, but current evidence is insufficient to say they reliably treat major depressive disorder.

Safety and tolerability

The review did not identify any class of nutraceuticals or phytoceuticals that was clearly less tolerable than placebo across the board. There were exceptions: citicoline was associated with higher dropout rates in the trials that reported tolerability data. A larger concern is incomplete reporting. Many trials did not provide enough information to assess long-term safety or rare but serious outcomes, including suicidality.

Why this matters for clinicians and patients

Supplements are accessible and often perceived as benign. That reality increases the importance of rigorous evidence. Patients and clinicians should weigh three facts: potential mechanisms exist for some compounds, the current clinical data are noisy, and harms and interactions are not well characterized in many studies. Combining caution with curiosity is the sensible path.

Expert Insight

'The study is useful because it parses the noise,' said Dr. Laura Benson, a clinical psychiatrist and researcher not involved in the review. 'It tells us where the signal might be and where the noise dominates. For EPA, the sample size gives us reason to study it further in large, well-controlled trials. For vitamin D3 and specific St. John’s wort extracts, I would want replication in diverse populations before recommending them as alternatives to established treatments.'

Implications and next steps for research

The authors call for higher-quality randomized trials targeted at the most promising compounds. That means larger sample sizes, rigorous double-blinding, longer follow-up, and transparent safety reporting. Head-to-head comparisons with standard antidepressants could also help place any effect in clinical context.

There are practical research angles worth pursuing. For EPA, dose-response relationships and the role of baseline dietary omega-3 status deserve attention. For vitamin D3, participant baseline deficiency may determine who benefits. For St. John’s wort extracts, chemical standardization and interactions with other medications are key concerns.

Conclusion

The bottom line is cautious optimism coupled with humility. A few nutraceuticals and plant extracts show promise in randomized trials, but the overall confidence in the evidence is low to very low. This review narrows the field for future study: EPA, vitamin D3, and certain St. John’s wort extracts merit further rigorous investigation, but current data do not support wide clinical adoption as standalone depression treatments.